Pfizer (PFE) News Today

Pfizer Inc. (PFE) is experiencing mixed investor sentiment driven by its dividend appeal, updated earnings forecasts, regulatory developments around vaccine advisory panels, and potential U.S. drug‐pricing reforms.

• Ranked among ultra-high-yield dividend stocks by Wall Street analysts, supporting income-oriented buying.
• Surge in bullish options activity ahead of its upcoming earnings report suggests optimistic positioning.
• Cantor Fitzgerald lifted its FY2026 EPS estimate to $3.10 (versus a $2.95 consensus) but maintained a Neutral rating and $24 price target.
• Shares traded higher intraday amid broad healthcare sector strength and anticipation of near-term catalysts.
• Barron’s notes Pfizer stock is shrugging off Robert F. Kennedy Jr.’s overhaul of CDC vaccine advisors, with investors awaiting the new ACIP lineup.
• A Seeking Alpha analysis flags Pfizer’s high dividend yield against looming patent expirations, underscoring a mixed risk/reward profile.
• Management reiterated no binding commitments on drug pricing during recent meetings with the U.S. government, reducing some policy uncertainty.
• CEO Albert Bourla’s remarks on pricing pressure and the company’s presentation at Goldman Sachs’ healthcare conference added strategic context.
• Despite underperforming the market year-to-date, analysts point to pipeline successes and cost-cutting measures as potential turnaround drivers.
• Zacks highlights elevated investor attention on factors—such as new product launches and margin improvements—that could influence Pfizer’s stock.
• A sweeping CDC vaccine advisory‐panel overhaul triggered after-hours and intraday share declines amid guidance uncertainty.
• Moderna, Pfizer and BioNTech shares dipped on news of the CDC panel shakeup, reflecting broader biotech volatility.
• Potential U.S. drug‐pricing reforms under discussion with the Trump administration continue to pressure valuations.